Search results
Results from the WOW.Com Content Network
– For more information visit alzheimers.org.uk/checklist or call the Alzheimer’s Society’s dementia support line on 0333 150 3456. Show comments Advertisement
How a new FDA-approved drug can — and can’t — help people with Alzheimer’s November 21, 2024 at 12:28 PM If you have a loved one with Alzheimer’s disease, you may have read about a newly ...
Aducanumab, sold under the brand name Aduhelm, is a monoclonal antibody designed to treat Alzheimer's disease. [2] [3] It is a monoclonal antibody [3] [2] that targets aggregated forms (plaque) [4] [5] of amyloid beta (Aβ) found in the brains of people with Alzheimer's disease to reduce its buildup.
The drug, and another new drug for Alzheimer’s called lecanemab, have been billed as a huge step forward in research because they target a known cause of the disease, rather than just treating ...
An Alzheimer’s disease drug may soon have a new dosing schedule. The medication, Leqembi, is currently administered via an infusion every two weeks. Under the proposed changes, the medication ...
BLAZE was a phase II study that also concluded in 2014 and evaluated the effects of crenezumab in patients with mild-to-moderate Alzheimer's Disease, however its primary endpoint was changes in brain amyloid load, with secondary endpoints of changes in other biomarkers, cognition, global function, and activities of daily living. The resultant ...
Lecanemab (a.k.a. leqembi) has received full approval from the U.S. Food and Drug Administration. This is the first FDA-approved treatment to help slow the progression of Alzheimer’s disease.
The FDA was expected to approve the drug in early 2024 but delayed its approval of the drug due to questions about the adverse effects of the drug, which were as severe as brain swelling and death.